BofA update shows where active managers are putting money
Investing.com - Cantor Fitzgerald maintained its Overweight rating and $16.00 price target on NeuroPace Inc (NASDAQ:NPCE) on Monday following the company’s announcement of a new chief financial officer.
NeuroPace announced Monday the appointment of Patrick Williams as Chief Financial Officer, effective June 20, 2025. Williams succeeds Rebecca Kuhn, who is departing after serving 25 years with the medical device company.
The incoming CFO brings over 25 years of experience at public medical device companies to NeuroPace. Williams most recently served as CFO of STARR Surgical, according to Cantor Fitzgerald.
Despite the leadership change, Kuhn will remain with NeuroPace in an advisory capacity for 12 months to ensure a smooth transition in the financial leadership role.
Cantor Fitzgerald maintained its $16.00 price target on NeuroPace stock, reflecting the firm’s continued confidence in the company’s financial outlook following the executive transition.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.